MedTrace Logo

Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

NCT07289503 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-12-17

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.

Conditions

Interventions

BIOLOGICAL

ABO1105

Formulation for injection

DRUG

Placebo

0.9% sodium chloride (normal saline) injection

Sponsors & Collaborators

  • Abogen Biosciences (Shanghai) Co., Ltd

    collaborator INDUSTRY

  • Suzhou Abogen Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2025-09-04
Completion
2026-06-27

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07289503 on ClinicalTrials.gov